Send to

Choose Destination
See comment in PubMed Commons below
Hematol Oncol. 2011 Dec;29(4):167-76. doi: 10.1002/hon.989. Epub 2011 Apr 2.

Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.

Author information

Division of Hematology, Department of Experimental Medicine and Oncology, University of Torino, Turin, Italy.


Early identification of patients at high risk of relapse is a major goal of current translational research in oncohematology. Minimal residual disease (MRD) detection by polymerase chain reaction-based methods is currently part of the routine clinical management of patients with acute lymphoblastic leukemia. However, the current knowledge indicates that it is also a useful prognostic tool in several mature lymphoproliferative disorders. Its utility is currently well established in follicular lymphoma, mantle cell lymphoma, and multiple myeloma. In some of these entities, clinical trials employing MRD as a decision-making tool are currently ongoing. In the present review, we will discuss the 'state of the art' of MRD evaluation in these three neoplasms with the ultimate aim of providing critical take-home messages for clinicians working in the field. Moreover, we will outline the role of MRD detection in the design of future clinical trials.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center